Chronic hepatitis B
Conditions
Interventions
Sponsors
The Fifth People's Hospital of Suzhou
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 65 years old, male or female (including 18 and 65); 2. HBV DNA < 2 x 10^8 IU/ml; 3. High level of core antibody quantitative assay (qAnti-HBc) at baseline; 4. Negative urine or serum pregnancy test within 24 hours before the first medication (for women of childbearing age); 5. The patient cooperated actively with good compliance and was willing to accept treatment and sign informed consent file.
Exclusion criteria
Exclusion criteria: 1. Liver function injury of other causes, such as cirrhosis, other viral hepatitis (hepatitis A, C, D, E or G), alcoholic hepatitis, autoimmune liver injury, drug-induced liver injury, etc. 2. Patients with HIV infection or other immunodeficiency diseases; 3. History of mental illness (schizophrenia or major depression), uncontrolled epilepsy, decompensated cirrhosis, uncontrolled autoimmune diseases; 4. Serious infections, retinal diseases, heart failure, chronic obstructive pulmonary disease and other basic diseases; 5. Patients complicated with serious diseases of heart, lung, kidney, brain, blood or other important organs, and patients complicated with other malignant tumors; 6. Pregnant or lactating women or patients who had pregnancy plans during the study period and were unwilling to use contraception; 7. Patients with other serious complications (such as severe infection, gastrointestinal bleeding, hepatorenal syndrome); 8. Relative contraindications: thyroid disease, previous history of depression, uncontrolled diabetes, heart disease; 9. Patients who are allergic to interferon and its drug components, and patients who are allergic to aspirin and its drug components, or the researchers judge that patients are not suitable for the application of interferon or aspirin; 10. Those who cannot comply with the study arrangement and sign the informed consent file; 11. Other conditions that the researcher judged inappropriate for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBV DNA;HBsAg. HbsAb. HbeAg. HbeAb. HbcAb;ALT. AST;TBIL. DBIL; | — |
Countries
China
Contacts
Public ContactZheng Hui
Soochow University
Outcome results
None listed